News

Eli Lilly and Company: Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics ...
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc.
TipRanks on MSN2d
Eli Lilly completes acquisition of Verve Therapeutics
Eli Lilly and Company (LLY) announced the successful completion of its acquisition of Verve Therapeutics. (VERV). Verve is a Boston-based ...
Lilly and Verve announce expiration of Verve tender offer
Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to ...
Eli Lilly Advances Pipeline and Gene Focus With Verve Acquisition
Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...
Penn CRISPR science is the foundation for a gene-editing heart disease treatment under Eli Lilly
Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, thinks it’s possible. Musunuru ...